$117 Million is the total value of Flagship Ventures 2007 General Partner LLC's 4 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGIO | Sell | Agios Pharmaceuticals, Inc. | $88,450,000 | -41.5% | 1,930,369 | -50.0% | 75.54% | +13.9% |
| EBIO | Eleven Biotherapeutics, Inc. | $25,134,000 | -18.8% | 1,907,008 | 0.0% | 21.46% | +58.1% | |
| BGMD | BG Medicine, Inc. | $1,853,000 | -45.3% | 1,764,286 | 0.0% | 1.58% | +6.5% | |
| REGI | New | Renewable Energy Group, Inc. | $1,659,000 | – | 144,630 | +100.0% | 1.42% | – |
| RCPT | Exit | Receptos, Inc. | $0 | – | -1,011,911 | -100.0% | -18.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGIOS PHARMACEUTICALS INC | 10 | Q2 2016 | 90.4% |
| ELEVEN BIOTHERAPEUTICS INC | 9 | Q2 2016 | 21.5% |
| BG Medicine, Inc. | 8 | Q3 2015 | 1.6% |
| RENEWABLE ENERGY GROUP INC | 8 | Q2 2016 | 1.4% |
| Seres Therapeutics, Inc. | 3 | Q4 2015 | 13.8% |
| Receptos, Inc. | 2 | Q1 2014 | 29.8% |
| SELECTA BIOSCIENCES INC | 1 | Q2 2016 | 21.5% |
| Tetraphase Pharmaceuticals, Inc. | 1 | Q4 2013 | 10.1% |
View Flagship Ventures 2007 General Partner LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2019-10-31 |
| 4 | 2019-05-15 |
| 3 | 2019-05-08 |
| 4 | 2019-05-06 |
| 3 | 2019-05-01 |
| 4 | 2019-03-06 |
| 3 | 2019-02-27 |
| 13F-NT | 2017-11-03 |
| 13F-NT | 2017-08-02 |
| 13F-NT | 2017-05-10 |
View Flagship Ventures 2007 General Partner LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.